ASX:EMD

Emyria Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume471,333 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Emyria (ASX:EMD) Vs. 1ST, ALC, BNVIF, CNNA, CNONF, and DOCRF

Should you be buying EMD stock or one of its competitors? Companies in the industry of "health information services" are considered alternatives and competitors to Emyria, including 1st Group (1ST), Alcidion Group (ALC), Binovi Technologies (BNVIF), Cann American (CNNA), CannaOne Technologies (CNONF), and CloudMD Software & Services (DOCRF).

Emyria (ASX:EMD) and 1st Group (ASX:1ST) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares Emyria and 1st Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EmyriaN/AN/AN/A
1st GroupN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings for Emyria and 1st Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emyria0000N/A
1st Group0000N/A

Valuation & Earnings

This table compares Emyria and 1st Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emyria$1.73 million0.00$-5,638,000.00A($0.03)N/A
1st Group$5.11 million0.00$-4,246,169.92A($0.01)N/A

1st Group has higher revenue and earnings than Emyria.

Summary

1st Group beats Emyria on 3 of the 3 factors compared between the two stocks.

Emyria (ASX:EMD) and Alcidion Group (ASX:ALC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Emyria and Alcidion Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emyria0000N/A
Alcidion Group0000N/A

Earnings and Valuation

This table compares Emyria and Alcidion Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emyria$1.73 million0.00$-5,638,000.00A($0.03)N/A
Alcidion Group$21.55 million0.00$-2,972,082.05A$0.00N/A

Alcidion Group has higher revenue and earnings than Emyria.

Profitability

This table compares Emyria and Alcidion Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EmyriaN/AN/AN/A
Alcidion GroupN/AN/AN/A

Summary

Alcidion Group beats Emyria on 3 of the 3 factors compared between the two stocks.

Emyria (ASX:EMD) and Binovi Technologies (OTCMKTS:BNVIF) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Profitability

This table compares Emyria and Binovi Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EmyriaN/AN/AN/A
Binovi TechnologiesN/AN/AN/A

Earnings & Valuation

This table compares Emyria and Binovi Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emyria$1.73 million0.00$-5,638,000.00A($0.03)N/A
Binovi TechnologiesN/AN/AN/AN/AN/A

Binovi Technologies has lower revenue, but higher earnings than Emyria.

Analyst Recommendations

This is a summary of current recommendations for Emyria and Binovi Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emyria0000N/A
Binovi Technologies0000N/A

Summary

Emyria beats Binovi Technologies on 1 of the 1 factors compared between the two stocks.

Emyria (ASX:EMD) and Cann American (CNSX:CNNA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Profitability

This table compares Emyria and Cann American's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EmyriaN/AN/AN/A
Cann AmericanN/AN/AN/A

Earnings & Valuation

This table compares Emyria and Cann American's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emyria$1.73 million0.00$-5,638,000.00A($0.03)N/A
Cann AmericanN/AN/AN/AN/AN/A

Cann American has lower revenue, but higher earnings than Emyria.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Emyria and Cann American, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emyria0000N/A
Cann American0000N/A

Summary

Emyria beats Cann American on 1 of the 1 factors compared between the two stocks.

Emyria (ASX:EMD) and CannaOne Technologies (OTCMKTS:CNONF) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Emyria and CannaOne Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emyria0000N/A
CannaOne Technologies0000N/A

Profitability

This table compares Emyria and CannaOne Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EmyriaN/AN/AN/A
CannaOne TechnologiesN/AN/AN/A

Earnings & Valuation

This table compares Emyria and CannaOne Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emyria$1.73 million0.00$-5,638,000.00A($0.03)N/A
CannaOne TechnologiesN/AN/AN/AN/AN/A

CannaOne Technologies has lower revenue, but higher earnings than Emyria.

Summary

Emyria beats CannaOne Technologies on 1 of the 1 factors compared between the two stocks.

CloudMD Software & Services (OTCMKTS:DOCRF) and Emyria (ASX:EMD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares CloudMD Software & Services and Emyria's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CloudMD Software & ServicesN/AN/AN/A
EmyriaN/AN/AN/A

Earnings & Valuation

This table compares CloudMD Software & Services and Emyria's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CloudMD Software & ServicesN/AN/AN/AN/AN/A
Emyria$1.73 million0.00$-5,638,000.00A($0.03)N/A

CloudMD Software & Services has higher earnings, but lower revenue than Emyria.

Analyst Recommendations

This is a summary of current ratings and recommmendations for CloudMD Software & Services and Emyria, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CloudMD Software & Services00203.00
Emyria0000N/A

CloudMD Software & Services presently has a consensus target price of $3.3750, indicating a potential upside of 113.61%.


Emyria Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
1st Group logo
1ST
1st Group
0.5N/AN/A$0.00$5.11 million0.00High Trading Volume
Gap Up
ALC
Alcidion Group
0.5N/AN/A$0.00$21.55 million0.00High Trading Volume
Gap Up
Binovi Technologies logo
BNVIF
Binovi Technologies
0.0$0.06flat$0.00N/A0.00News Coverage
Gap Down
CNNA
Cann American
0.5N/AN/A$0.00N/A0.00High Trading Volume
CannaOne Technologies logo
CNONF
CannaOne Technologies
0.6$1.03flat$0.00N/A0.00
CloudMD Software & Services logo
DOCRF
CloudMD Software & Services
1.7$1.58flat$0.00N/A0.00Gap Up
DOC
CloudMD Software & Services
1.2$1.93flatC$0.00C$11.65 million-21.44
CGS
Cogstate
0.5N/AN/A$0.00$28.82 million0.00High Trading Volume
Gap Up
COO
Corum Group
0.5N/AN/A$0.00$12.27 million0.00High Trading Volume
EGF Theramed Health logo
EVAHF
EGF Theramed Health
0.0$0.10flat$0.00N/A0.00
EWLL
eWellness Healthcare
0.6$0.00flat$0.00N/A0.00Gap Up
FORA
Forian
0.3$12.20flat$0.00N/A0.00
GLH
Global Health
0.5N/AN/A$0.00$6.77 million0.00High Trading Volume
Gap Up
ICS
ICS Global
0.9N/AN/A$0.00$6.08 million0.00High Trading Volume
Gap Up
JHL
Jayex Healthcare
0.7N/AN/A$0.00$6.61 million0.00High Trading Volume
Gap Up
M3 logo
MTHRF
M3
1.0$76.00flat$0.00N/A0.00
M7T
Mach7 Technologies
0.6N/AN/A$0.00$16.89 million0.00High Trading Volume
Gap Up
MDR
MedAdvisor
0.5N/AN/A$0.00$18.09 million0.00High Trading Volume
Gap Up
NEWUF
Newtopia
1.7$0.41flat$0.00N/A0.00
NHL
Novita Healthcare
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
ONE
Oneview Healthcare
0.5N/AN/A$0.00$7.10 million0.00High Trading Volume
OPL
Opyl
0.0N/AN/A$0.00$741,494.000.00High Trading Volume
PCK
PainChek
0.0N/AN/A$0.00$240,424.000.00High Trading Volume
PANHF
Ping An Healthcare and Technology
1.0$12.01flat$0.00N/A0.00News Coverage
PKS
PKS
0.0N/AN/A$0.00$5.97 million0.00High Trading Volume
PME
Pro Medicus
0.7N/AN/A$0.00$59.12 million0.00High Trading Volume
Gap Up
Pro Medicus logo
PMCUF
Pro Medicus
0.5$35.65flat$0.00N/A0.00
RAP
ResApp Health
0.9N/AN/A$0.00$46,197.000.00High Trading Volume
Gap Up
CBIIF
Skylight Health Group
0.0$0.91flat$0.00N/A0.00News Coverage
TD1
TALi Digital
0.5N/AN/A$0.00$706,550.000.00High Trading Volume
UCBB
US-China Biomedical Technology
0.3$0.34flat$0.00N/A0.00Gap Down
WELL Health Technologies logo
WLYYF
WELL Health Technologies
1.6$5.72flat$0.00N/A0.00
ZMD
ZoomMed
0.4$0.02flatC$0.00C$10,000.00-1.36Gap Down
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.